BioCentury
ARTICLE | Clinical News

Influenza DNA vaccine: Final Phase I data

February 23, 2009 8:00 AM UTC

Final data from a double-blind, dose-escalation, U.S. Phase I trial in 100 healthy volunteers showed that 75%-100% of evaluable patients receiving monovalent Vaxfectin-formulated H5N1 pandemic influen...